Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

CEVEC Pharmaceuticals GmbH, corporate

CEVEC Pharmaceuticals GmbH,

02.02.2021 - 14:04:04

CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP Technology in anti-tumor cell therapies

and follow us on LinkedIn

About CARISMA Therapeutics Inc.:

CARISMA Therapeutics Inc. is a biopharmaceutical company developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. CARISMA Therapeutics is headquartered in Philadelphia, PA.

For more information, please visit www.carismatx.com.

Contact:

CEVEC Pharmaceuticals GmbH MC Services AG Dr. Ulrich Kettling Dr. Solveigh M?hler Chief Business Officer Public Relations T.: +49 221 460 208 00 E.: info@cevec.com T.: +49 211 529 252 19 E.: solveigh.maehler@mc-services.eu ? ? CARISMA Therapeutics Inc. ? Christina Khoury-Folkens Media Relations T.: +1 612 806 0757 E.: ckhoury@w2ogroup.com ?

02.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

1164784??02.02.2021?

@ dgap.de